| Intrinsic Valuation of: MAXHEALTH | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 14 | Market Cap | ₹1,022B | |||||
| 2021 | - | - (-) | P/E Ratio | 72 | Total Asset | ₹152B | |||||
| 2022 | ₹2B | - (-) | Net Income | ₹11B | Total Debt | ₹23B | |||||
| 2023 | ₹9B | 406.7% (338.4%) | EBITDA | ₹19B | Total Liab | ₹58B | |||||
| 2024 | ₹3B | -64.6% (-70.1%) | Opr Margin | 22.81 | Debt/Equity | 0.24 | |||||
| 2025 | ₹5B | 47.1% (13.0%) | PreTax Margin | 20.66 | BV/Share | 34 | |||||
| 5Y Average FCF | ₹5B | 15.0% (93.8%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.48% | Historical US Bond Yield: | 4.40% | ||||||||
| Discount Rate (WACC): | 7.00% | Current US Bond Yield: | 3.48% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (15.0%) | ||||||||||
| 2026 | ₹6B | MBG Intrinsic Value | ₹130 | ||||||||
| 2027 | ₹6B | ||||||||||
| 2028 | ₹7B | ||||||||||
| 2029 | ₹8B | ||||||||||
| 2030 | ₹8B | ||||||||||
| 2031 | ₹8B | ||||||||||
| Terminal Value | ₹184B | Net Worth/Share | ₹96 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹156B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹7B | ₹144 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹23B | WACC | 6.5% | 134 | 147 | 164 | 186 | 214 | |||
| Equity Value | ₹140B | 7.1% | 117 | 127 | 140 | 155 | 175 | ||||
| Shares Outstanding | 973,243,789 | 7.8% | 103 | 111 | 121 | 132 | 146 | ||||
| 8.4% | 92 | 98 | 106 | 114 | 125 | ||||||
| DCF Intrinsic Value | ₹144 | 9.0% | 83 | 88 | 94 | 101 | 109 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||